Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
23.12.2021 17:06:00 EET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abbove strengthens its banking position with the deployment of its platform at ING in Belgium11.6.2026 07:10:00 EEST | Press release
Belgian WealthTech Abbove announces the deployment of its wealth planning platform at ING Belgium. The bank is making a new digital wealth planning experience, ING Financial Compass, available to its Personal Banking and Private Banking clients, built on Abbove technology and specially adapted to its advisory model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610237679/en/ ING Belgium trusts Abbove's technology This collaboration marks a new step in Abbove's development among European financial institutions and reflects how the expectations of banks and their clients are shifting towards a more global approach to wealth guidance. A platform configured for ING Belgium's specific needs While ING Financial Compass is built on Abbove's technological foundation, the solution has been configured to meet the specific needs of ING Belgium, its advisors and its clients. The client journeys, advisory methodologies and wealth obj
Clip Launches Mi Clip, a Digital Wallet Ecosystem, by Partnering with Ant International, Mastercard and Televisa-Univision11.6.2026 07:01:00 EEST | Press release
Clip, Mexico’s premier financial ecosystem, announced today the launching of Mi Clip, a digital wallet ecosystem designed to accelerate the adoption of digital payments, drive acceptance across merchants and consumers nationwide, and expand access to formal financial services for millions of Mexicans. Mi Clip is supported by commercial and technological solutions from Clip’s payment platform, Ant International’s AI technology, Mastercard’s trusted global payments network and Televisa-Univision’s media outreach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610247747/en/ Through the initiative, users will be able to access digital wallet accounts that support everyday payments, financial services, and inclusive credit solutions. The wallet is also designed to provide a formal financial identity. Connecting global financial technology expertise with unmatched local reach, Mi Clip aims to help drive Mexico’s digital economy
MTN Group Fintech Advances Digital Transformation Through Strategic Technology Partnership11.6.2026 05:00:00 EEST | Press release
MTN Group Fintech has entered into a strategic partnership with Ant International, a leading global digital payment, digitisation and financial technology provider, to accelerate the transformation of its mobile money ecosystem. The partnership, which is expected to launch in Nigeria next quarter, will introduce a super-app platform designed to enhance user experience, deepen digital inclusion and enable a next-generation ecosystem for digital finance, lifestyle and commerce services around MoMo. By leveraging Ant International’s advanced technology, MTN is evolving MoMo to enable stronger ecosystem integration through a mini app platform, enhanced fraud prevention and richer engagement features for consumers and merchants. The partnership represents a major step in building a more resilient and future-ready digital ecosystem. “This partnership aligns with MTN Group’s ambition of leading digital solutions for Africa’s progress by leveraging scale, technology and strong global partnersh
TestMu AI Announces Day-Zero Support for macOS Golden Gate and iOS 27 Beta Following WWDC 202610.6.2026 22:52:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced day-zero support for Apple's newly unveiled operating systems, macOS Golden Gate and iOS 27 Beta, across its cloud testing platform. Announced at Apple's Worldwide Developers Conference (WWDC) 2026, macOS Golden Gate and iOS 27 introduce significant platform updates that will impact application compatibility, user experience, and performance. Both operating systems are now available for testing on TestMu AI, the same day Apple released its beta versions, allowing engineering teams to identify issues months before the stable rollout reaches millions of users worldwide. macOS Golden Gate is available through the TestMu AI Real Time Testing platform, while iOS 27 Beta is available on TestMu AI Real Device Cloud across the latest iPhones and iPads. "WWDC marks the start of a critical testing window for every team that ships on Apple platforms," said Mudit Singh, Co-Founder
Pure Lithium Corporation Named World Economic Forum Technology Pioneer10.6.2026 21:10:00 EEST | Press release
Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the company has been selected as a 2026 Technology Pioneer by the World Economic Forum. Launched in 2000, the Technology Pioneers is a leading community for companies from around the world that are shaping the future through breakthrough technologies and innovations. These companies are selected for their potential to have a significant impact on business and society and are invited to engage with public and private sector leaders through the World Economic Forum’s global platform. “We are delighted to be selected as a World Economic Forum Technology Pioneer. I would like to express my gratitude to the World Economic Forum for this honor,” said Pure Lithium Founder, Chairman and CEO, Emilie Bodoin. “Pure Lithium’s selection is a testament to our breakthrough lithium metal battery technology. We are constantly reminded of the urgent need for a battery that is more energy efficien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom